Fig. 2From: Co-administration of iloprost and eptifibatide in septic shock (CO-ILEPSS)—a randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacya–g Comparison of time-dependent changes in absolute biomarker values. Data shown as median (IQR). *Within-group change from baseline, p < 0.05; #within-group change from non-baseline, p < 0.05. sVEGFRI soluble vascular endothelial growth factor receptor 1Back to article page